Skip to main content
Rohit Singh, MD, Oncology, Burlington, VT

RohitSinghMD

Oncology Burlington, VT

Melanoma, Thoracic Cancer

Assistant Professor, Division of Hematology Oncology, Larner College of Medicine University of Vermont Cancer Center

Dr. Singh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Singh's full profile

Already have an account?

  • Office

    111 Colchester Ave
    Burlington, VT 05401
    Phone+1 802-847-8400

Summary

  • As a dedicated medical oncologist with a specialization in immuno-oncology, I am passionate about improving the lives of patients battling thoracic and cutaneous cancers. My journey in medicine began in India, where I laid the foundation for my career. I then advanced my expertise through an internal medicine residency at the Yale University Waterbury Center in Connecticut. Following this, I completed a rigorous hematology-oncology fellowship at the University of Vermont, where I honed my skills and deepened my commitment to patient care. Today, I am proud to continue my practice here, where I strive to make a meaningful difference in the lives of those I treat.

Education & Training

  • Pt. B.D. Sharma Postgrad Institute of Medical Science
    Pt. B.D. Sharma Postgrad Institute of Medical ScienceClass of 2015, MD

Certifications & Licensure

  • VT State Medical License
    VT State Medical License 2024 - 2026
  • CT State Medical License
    CT State Medical License 2023 - 2024
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Merit award for an abstract ESMO, 2023
  • Editorial fellow Journal of Clinical Oncology, 2023
  • Intern of the Year Yale-Waterbury medicine residency, 2019

Publications & Presentations

PubMed

Press Mentions

  • JCO Article Insights: Atezolizumab plus Bevacizumab, Chemotherapy in EGFR, ALK NSCLC
    JCO Article Insights: Atezolizumab plus Bevacizumab, Chemotherapy in EGFR, ALK NSCLCApril 29th, 2024

Professional Memberships